No Big Surprises From Lilly: Management Sticks To Its Guns On Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
With the loss of Zyprexa just months away, Eli Lilly management sought to reassure investors its strategy of focusing on its internal pipeline and core growth areas will pay off post-2014.
You may also be interested in...
Lilly BioMedicines Head Ricks Tasked With Overseeing Growth Phase As Next CEO
Long-time CEO John Lechleiter, who led the company through a challenging period of enormous patent expirations, will step down at year's end.
Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
Failure to perform better than placebo in the first of two pivotal Phase III trials diminishes chances of success for pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist that Lilly hoped to position as a successor to its patent-expired schizophrenia therapy Zyprexa.
Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
Failure to perform better than placebo in the first of two pivotal Phase III trials diminishes chances of success for pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist that Lilly hoped to position as a successor to its patent-expired schizophrenia therapy Zyprexa.